



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	09/996,069
Filing Date	November 27, 2001
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	M1015.70071

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
MY ↓	A1	US- 3,854,480	12-17-1974	ZAFFARONI	whole document
	A2	US- 4,452,775	06-05-1984	KENT	whole document
	A3	US- 4,675,189	06-23-1987	KENT et al.	whole document
	A4	US- 5,075,109	12-24-1991	TICE et al.	whole document
	A5	US- 5,133,974	07-28-1992	PARADISSIS et al.	whole document
	A6	US- 5,407,686	04-18-1995	PATEL et al.	whole document
	A7	US- 5,736,152	04-07-1998	DUNN	whole document
	A8	US- 6,127,393	10-03-2000	FERNANDEZ-POL	whole document
	A9	US- 6,548,643 B1	04-15-2003	MCKENZIE et al.	whole document
	A10	US- 2003/0130293 A1	07-10-2003	BAMDAD	whole document
	A11	US- 2003/0119834 A1	06-26-2003	BAMDAD	whole document
	A12	US- 2002/0156112 A1	10-24-2002	BAMDAD et al.	whole document
	A13	US- 09/631,818 (08-03-2000)		BAMDAD	whole document
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
MY ↓	B1	WO 92/07000 French, English Abs	04-30-1992	CHAMBON et al.	whole document	✓
	B2	WO 95/24929	09-21-1995	MATHIOWITZ et al.	whole document	
	B3	WO 00/34783	06-15-2000	BERGSMA et al.	whole document	
	B4	WO 00/43791 ✓	07-27-2000	BAMDAD et al.	whole document	
	B5	WO 02/056022 A2	07-18-2002	BAMDAD et al.	whole document	
	B6	WO 02/078598 A2	10-10-2002	WRESCHNER et al.	whole document	

Examiner
Signature

/Misook Yu/

Date
Considered

10/17/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	09/996,069
Filing Date	November 27, 2001
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	M1015.70071

Sheet	2	of	2
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	FOREIGN PATENT DOCUMENTS				
		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ^o
		Country Code ² -Number ⁴ -Kind Code ³ (if known)	MM-DD-YYYY			
MY	B7	WO 02/22685 A2	03-21-2002	KUFE et al.	whole document	
↓	B8	WO 03/020279 A2	03-13-2003	BAMDAD	whole document	
	B9	WO 03/020280 A2	03-13-2003	BAMDAD	whole document	
	B10	WO 03/089451 A2	10-30-2003	HOOGENBOOM et al.	whole document	
	B11	WO 2004/005470 A2	01-15-2004	PAYNE et al.	whole document	
	B12	WO 2005/019269 A2	03-03-2005	BAMDAD	whole document	

Examiner Signature	/Misook Yu/	Date Considered	10/17/2006
-----------------------	-------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 1 of 2	Application Number	09/996,069
	Filing Date	November 27, 2001
	First Named Inventor	BAMDAD, Cynthia C.
	Art Unit	1645
	Examiner Name	N/A
Attorney Docket Number		M1015.70071

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY	C1	MEERZAMAN et al., "Involvement of the MAP kinase ERK2 in MUC1 mucin signaling", Am. J. Physiol. Lung Cell Mol. Physiol. (2001), 281: L86-L91	
	C2	SPICER et al., "Molecular Cloning and Analysis of the Mouse Homologue of the Tumor-associated Mucin, MUC1, Reveals Conservation of Potential O-Glycosylation Sites, Transmembrane, and Cytoplasmic Domains and a Loss of Minisatellite-like Polymorphism", The Journal of Biological Chemistry (1991), 266(23): 15099-15109	X
	C3	VARNER et al., "Integrins and cancer", Current Opinion in Cell Biology (1996), 8: 724-730	
	C4	HORTON, "The avb3 Integrin "Vitronectin Receptor", Int. J. Biochem. Cell Biol. (1997), 29(5): 721-725	
	C5	ROSS et al., "The HER-2/neu Oncogene in breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy", Stem Cells (1998), 16: 413-428	
	C6	TREON et al., "MUC-1 Core Protein is Expressed on Multiple Myeloma Cells and is Induced by Dexamethasone", Blood (1999), 93(4): 1287-1298	
	C7	LIGTENBERG et al., "Cell-associated Episialin is a Complex Containing Two Proteins Derived from a Common Precursor", The Journal of Biological Chemistry (1992), 267(9): 6171-6177	
	C8	CHEN et al., "Labeling of Proteins with [35S]Methionine and/or [35S]Cysteine in the Absence of Cells", Analytical Biochemistry (1999), 269: 179-188	
	C9	SAWHNEY et al., "Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(a-hydroxy acid) Diacrylate Macromers", Macromolecules (1993), 26: 581-587	
↓	C10	HIEKEN et al., "beta3 Integrin Expression in Melanoma Predicts Subsequent Metastasis", Journal of Surgical Research (1996): 63(1): 169-173(5)	

Examiner Signature	/Misook Yu/	Date Considered	10/17/2006
---------------------------	-------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 2 of 2

Application Number	09/996,069
Filing Date	November 27, 2001
First Named Inventor	BAMDAD, Cynthia C.
Art Unit	1645
Examiner Name	N/A
Attorney Docket Number	M1015.70071

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MY	C11	VAILHE et al., "In vitro angiogenesis is modulated by the mechanical properties of fibrin gels and is related to alpha(v)beta3 integrin localization", In Vitro Cell Dev. Biol. Anim. (1997), 33(10): 763-773	
	C12	PEGGRAM et al., "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment", Journal of Clinical Oncology (1998), 16: 2659-2671	
	C13	FRALEY et al., "New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids", Trends in Biochemical Sciences(1981), 6: 77-80	
	C14	KUFE et al., "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors", Hybridoma (1984), 3(3): 223-232	
	C15	SCHNEIDER et al., "nm23 expression in advanced and borderline ovarian carcinoma", Anticancer Res. (1996), 16(3A): 1197-1202	
	C16	MAO et al., "Loss of nm23 expression predicts distal metastases and poorer survival for breast cancer", Int. J. Oncol. (2001), 18(3): 587-591	
↓	C17	GREGORIADIS, "Liposomes for drugs and vaccines", Trends in Biotechnology (1985), 3(9): 235-241	

Examiner
Signature

/Misook Yu/

Date
Considered

10/17/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.